Overland Pharmaceuticals, backed by Hillhouse Capital, is building a fully integrated biopharma company with a mission to bring innovative medicines to underserved patients in Asia and around the world.
By leveraging our resources, global network, and local expertise across the biopharma ecosystem in Asia, Overland is establishing a portfolio of differentiated therapeutic candidates in a few carefully selected therapeutic areas.
Through formative R&D partnerships, Overland will move forward the development and commercialization of the most promising advances in medicine.
Through strategically engineered alliances, Overland focuses on innovative therapeutic programs and cutting-edge technology platforms to deliver maximum value to all stakeholders with the ultimate goal of serving patients around the world.
Overland’s flexible business approach and ability to architect differing partnership models (e.g. joint-venture, licensing, and equity investment deal structures), coupled with deep local expertise and a strong track record of achieving drug approvals in greater China, allows both Overland and its partners to benefit from each other’s respective strengths.
Therapeutic candidate programs across our portfolio are developed by our dedicated clinical and regulatory teams and other shared functional resources to achieve peak operational and capital efficiency.
We are committed to putting patients first and aim at fostering a culture of strong ethics and a high standard for quality.
We are launching a robust research and development engine of differentiated, novel therapeutics – all with the spirit and ambition of a nimble biotech.
Overland collaborates with innovative partners to jointly develop and strategically commercialize therapeutic programs for entry into Asia and expansion around the globe.
We accelerate the development of and access to promising new medicines for patients by sourcing the brightest talents and centralizing key operations.
Ed Zhang, MBA, serves as Co-founder and Interim CEO at Overland Pharmaceuticals, and Venture Partner, BioVenture at Hillhouse Capital.
Prior to Overland, Ed was VP of Corporate Development at Boston Pharmaceuticals, representing a new biotech business model focused on translational clinical development. As part of its founding team, Ed led corporate development and strategic initiatives including establishing partnerships with leading global pharma and biotech companies. Prior to joining Boston Pharma, Ed headed Global Business Development for Sanofi’s Renal Strategic Unit and was Director of Commercial Operations and Strategic Development at Genzyme before acquisition by Sanofi. Ed started his career as a medicinal chemist at Pharmacia & Upjohn and now brings over 17 years of biopharma industrial experience to Overland.
Ed holds an MBA from Kellogg School of Management at Northwestern University, an MS in chemistry from Binghamton University, and a BS from Nanjing University.
Jie Li serves as SVP, Head of Regulatory Affairs at Overland Pharmaceuticals.
Prior to Overland, Jie held different Regulatory Affairs positions at Pfizer China since 1999 and led the department from 2010 until April 2020. In this role, she supported all facets of Pfizer China’s pharma business for registration strategy of all new products including small and large molecule drugs, and vaccines, in addition to license maintenance of approved products. She proactively partnered with industry associations and government agencies to introduce international best practices into China for NMPA’s regulatory system reform. In addition to Pfizer, she has experience working at other MNCs, such as SmithKline Beecham China, BMS China and Wyeth. She has also served as the Co-Chair of Regulatory Affairs Working Group in RDPAC (R&D Based Pharmaceutical Association Committee) in China. Jie holds over 25 years of regulatory affairs experience covering multiple therapeutic areas including cardiovascular and metabolic disease, neuroscience, oncology, infectious disease, inflammation & immunology, rare disease, endocrinology, and vaccine.
Jie received her MS from Peking Union Medical Colleague and BS in Medicine from Beijing University of Traditional Chinese Medicine.
Dr. Jie Chen serves as SVP, Head of Biometrics at Overland Pharmaceuticals.
Prior to Overland, Dr. Chen was a distinguished scientist in biostatistics at Merck Research Laboratories (US). He previously worked in China as Senior Global Group Head of Biostatistics at Novartis and as Senior Director and Head of Biometrics & Information Sciences at AstraZeneca and Merck Serono. He is also a member of the China Tripartite Coordination Committee, responsible for drafting and revising technical guidance for drug development in China. Dr. Chen holds 25 years of experience in biopharmaceutical R&D and has been invited to present at FDA/industry statistics workshops, EMA statistics symposia, and numerous other venues.
Dr. Chen received his PhD in Statistics from Temple University, Philadelphia, and his MD degree from Shanghai Medical College, Fudan University.
Dr. Yi Feng serves as Vice President, Head of Oncology Clinical Science at Overland Pharmaceuticals.
Prior to Overland, Dr. Feng served as Senior Director of Oncology at Roche and led multiple successful registrational trials of Perjeta/Kadcyla/Herceptin SC/Tecentriq/Avastin for breast and gynecological cancers. Before joining Roche, Dr. Feng served as Associate Director at Merck Sharp & Dohme (MSD) working on Keytruda for gastric cancer, Therapeutic Area Lead for solid tumors at Janssen R&D working on Zytiga and Apalutamide for prostate cancer, and Medical Affair Manager at Novartis Oncology working on Ceritinib for non-small cell lung cancer. Previously, she also worked as Project Manager of Clinical Operations in oncology, diabetes mellitus, CVD, and nephrology for six years at Novartis, Sanofi-Aventis, and Novo Nordisk. Additionally, she worked at the Peking Union Medical College affiliated Hematology Hospital and Institute for seven years as a hematology physician and researcher before joining industry. Bringing over 15 years of industry experience, Dr. Feng has been actively involved in global and local registrational trials as well as successful NDA submissions in the US, EMA, and China.
Dr. Feng received her MS in Internal Medicine from Peking Union Medical College and her MD from Nanjing Medical University.
Kenneth Gao serves as VP of Alliance Management and Corporate Development at Overland Pharmaceuticals.
Prior to Overland, Kenneth most recently served as Senior Director of Corporate Development and Strategy as well as Head of China Operations at Assembly Biosciences. At Assembly Kenneth spearheaded establishment of Assembly China, led teams to execute strategic partnerships for assets in all development stages across the globe, and co-led multiple rounds of follow-on capital raising on Nasdaq. Before Assembly, he held various managerial positions in management consulting, transactions, and business operations at IMS Health, Eli Lilly, and Becton Dickinson. Kenneth also worked at Ennovance Capital, focused on mid-market private equity investments in the specialty chemical and pharmaceutical sectors.
Kenneth received an MBA in Health Sector Management from Duke University and a BS in Business Administration from State University of New York at Buffalo, NY.
Dr. Eric Hu serves as VP of Business Development at Overland Pharmaceuticals.
Prior to Overland, Dr. Hu was Senior Director of Business Development at Turning Point Therapeutics where he contributed to all aspects of strategic initiatives, deal sourcing, and diligence efforts. Before Turning Point Therapeutics, Dr. Hu spent over ten years at Gilead Sciences with increasing responsibilities from drug discovery to business development diligence. Dr. Hu is a coauthor of several high impact publications including Nature and Nature Medicine. Dr. Hu is also a key contributor and co-inventor of multiple clinical programs in antiviral, oncology, and inflammation including first-in-class long-acting HIV Capsid inhibitor Lenacapavir currently in multiple phase III clinical trials. Dr. Hu brings over 17 years of biopharmaceutical industry experience to Overland.
Dr. Hu received his Ph.D. in organic chemistry from University of California, Los Angeles, and BS from Beijing Normal University with honors.
ERIC KOO, MBA, B. Pharm, serves as CEO at Overland ADCT Biopharmaceuticals.
Prior to Overland ADCT, Eric was Vice President, Head of Oncology Business Unit at Takeda China focusing on multiple myeloma and lymphoma. Prior to joining Takeda, Eric served as Director, Oncology Business Unit and Director, Market Access, External Affairs & Key Account Management at Merck, Sharp and Dome (MSD) Taiwan. Prior to MSD, he served as Regional Marketing Director for APAC & Specialty Care BU Head, Malaysia/Singapore at Bayer APAC. Mr. Koo started his pharmaceutical career at Pfizer, spending 16 years in various sales, product management and marketing positions at both Pfizer Taiwan and Pfizer Emerging Market Asia & China, including 5 years as the China/APAC Regional Marketing Director for Oncology.
Mr. Koo earned his B. Pharmacy from Taipei Medical University and MBA from the University of North Carolina at Charlotte, Belk College of Business.